Promising Alzheimer's Drug Fails

March 2010
MondayMorning;3/8/2010, Vol. 18 Issue 9, p3
The article reports that the drug, dimebon, for treating Alzheimer's disease, failed in the initial stage of its clinical trial. It informs that dimebon showed no effect after six months in treating Alzheimer's disease. Earlier trials were successful and dimebon worked really good and showed better results in Alzheimer's disease patients.


Related Articles

  • Does new drug control progression? O'Connor, John // McKnight's Long-Term Care News;Apr2009, Vol. 30 Issue 4, p4 

    The article discusses a study that examined the efficacy of the investigational drug Bapineuzumab in slowing down the progression of Alzheimer's disease. The clinical study involved over 2,000 volunteers who participate in the third phase of the study in the U.S. The patients received the...

  • Lilly to Conduct Additional Study of Alzheimer's Drug. Eli Lilly & Co.  // MondayMorning;12/17/2012, Vol. 20 Issue 48, p1 

    The article reports that Eli Lilly & Co. has announced to conduct a study to examine the efficacy of its experimental drug, solanezumab, in improving the condition of people with Alzheimer's disease (AD). It mentions about the results of previous clinical trials run by the company that showed...

  • ALZHEIMER'S: TARGET UNMET NEEDS.  // Applied Clinical Trials;Apr2010, Vol. 19 Issue 4, p18 

    The article focuses on the development of drugs used for treating Alzheimer's disease in the U.S. It stresses the result of a clinical trial which examines the effectiveness of the drug dimebon, released by Pfizer Inc. and Medivation Inc. Results revealed that the investigational drug which is...

  • Biogen Drug Test Advances. Investor's Business Daily // Investors Business Daily;12/3/2014, pA01 

    2 The results from a 194-patient phase one trial for Alzheimer's drug BIIB-037 are good enough to jump to phase three, pending dosing issues,

  • Key Clinical Trial of Alzheimer's Disease Drug Begins in Europe.  // Biomedical Market Newsletter;2/21/2012, Vol. 21, p1 

    The article provides information on a European large scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute, Sarasota, Florida. The phase III trial designed to study the effectiveness of the medication will include more than 500 Alzheimer's patients...

  • The potential and limits for clinical trials for early Alzheimer’s disease and some recommendations. SCHNEIDER, L. S. // Journal of Nutrition, Health & Aging;Apr2010, Vol. 14 Issue 4, p295 

    Recommendations for clinical trials methods for ‘pre-dementia,’ ‘prodromal,’ or early Alzheimer’s disease are discussed. Early AD can be considered as subsets of both ‘amnestic MCI’ and ‘probable AD.’ In principle, it can be...

  • Unraveling the Alzheimer's Mystery. Docksai, Rick // Futurist;Sep/Oct2014, Vol. 48 Issue 5, p12 

    The article focuses on identification of genes associated with the Alzheimer's disease by international research partnerships. Topics discussed include importance of finding genes that give rise to Alzheimer's, the Dominantly Inherited Alzheimer Network (DIAN) trial for testing drugs Solanezumab...

  • Alzheimer's Disease Update.  // PharmaWatch: CNS;Mar2006, Vol. 5 Issue 3, p5 

    The article reports on developments about drugs for treating Alzheimer's disease. Neurochem Inc. will conduct a phase III extension clinical trial for Alzhemed. Amorfix Life Sciences and the Ontario Genomics Institute are collaborating to develop a blood test for Alzheimer's disease based upon...

  • Alzheimer’s treatment to enter second trial. Henderson, Tom // Crain's Detroit Business;6/6/2011, Vol. 27 Issue 23, p0006 

    The article focuses on the planned second clinical trial of a zinc-based treatment for Alzheimer's disease symptoms by Adeona Pharmaceuticals Inc. It says that the company will enroll over 100 patients aged 70 and above. It tells that if the trial succeed in proving the drugs' efficacy, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics